While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report) today and set a price target of $45.00. The company’s shares closed yesterday at ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Since then, Viking has reiterated this encouraging data from trials of the injectable candidate and reported favorable data ...

Read More Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which ...

根据最近的SEC文件显示，Viking Therapeutics, Inc. (NASDAQ:VKTX)的董事Macartney Lawson最近进行了几笔涉及公司股票的交易。2023年11月8日，Lawson以平均每股68.67美元的价格出售了2,000股Viking Therapeutics普通股，总销售额约为137,333美元。 除了出售股票外，Lawson还通过行权以每股5.80美元的价格 ...